Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Journal: Future oncology (London, England)
Published: December 22, 2018
Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Journal: Future oncology (London, England)
Published: October 11, 2018
Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Journal: Future oncology (London, England)
Published: June 07, 2018
Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Journal: Drug design, development and therapy
Published: March 15, 2018
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 15, 2015
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2013
Showing 1-6 of 6
Last Updated: 09/26/2026